Carrascosa J M, Rocamora V, Fernandez-Torres R M, Jimenez-Puya R, Moreno J C, Coll-Puigserver N, Fonseca E
Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.
Servicio de Dermatología, Hospital de Manacor, Manacor, Mallorca, España.
Actas Dermosifiliogr. 2014 Jan-Feb;105(1):31-44. doi: 10.1016/j.ad.2012.08.003. Epub 2012 Nov 23.
Obesity, particularly abdominal obesity, is currently considered a chronic low-grade inflammatory condition that plays an active role in the development of the pathophysiologic phenomena responsible for metabolic syndrome and cardiovascular disease through the secretion of proinflammatory adipokines and cytokines. In recent years clear genetic, pathogenic, and epidemiologic links have been established between psoriasis and obesity, with important implications for health. The relationship between the 2 conditions is probably bidirectional, with obesity predisposing to psoriasis and psoriasis favoring obesity. Obesity also has important implications in the treatment of psoriasis, such as a greater risk of adverse effects with conventional systemic drugs and reduced efficacy and/or increased cost with biologic agents, for which dosage should be adjusted to the patient's weight.
肥胖,尤其是腹型肥胖,目前被认为是一种慢性低度炎症状态,它通过分泌促炎脂肪因子和细胞因子,在导致代谢综合征和心血管疾病的病理生理现象的发展过程中发挥积极作用。近年来,银屑病与肥胖之间已明确建立了遗传学、病理学和流行病学联系,对健康具有重要影响。这两种情况之间的关系可能是双向的,肥胖易患银屑病,而银屑病也利于肥胖的发生。肥胖在银屑病治疗中也具有重要意义,例如使用传统全身性药物时出现不良反应的风险更高,使用生物制剂时疗效降低和/或成本增加,而生物制剂的剂量应根据患者体重进行调整。